These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21312012)

  • 1. Solution formulation development of a VEGF inhibitor for intravitreal injection.
    Marra MT; Khamphavong P; Wisniecki P; Gukasyan HJ; Sueda K
    AAPS PharmSciTech; 2011 Mar; 12(1):362-71. PubMed ID: 21312012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical challenges for developing long acting intravitreal medicines.
    Awwad S; Henein C; Ibeanu N; Khaw PT; Brocchini S
    Eur J Pharm Biopharm; 2020 Aug; 153():130-149. PubMed ID: 32445965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitreous pharmacokinetics and retinal safety of intravitreal preserved versus non-preserved triamcinolone acetonide in rabbit eyes.
    Oliveira RC; Messias A; Siqueira RC; Bonini-Filho MA; Haddad A; Damico FM; Maia-Filho A; Crispim PT; Saliba JB; Ribeiro JA; Scott IU; Cunha AS; Jorge R
    Curr Eye Res; 2012 Jan; 37(1):55-61. PubMed ID: 22029458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and pharmacokinetics of intravitreal sirolimus.
    Mudumba S; Bezwada P; Takanaga H; Hosoi K; Tsuboi T; Ueda K; Kawazu K; Ali Y; Naor J
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):507-14. PubMed ID: 22662868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.
    Ma F; Nan K; Lee S; Beadle JR; Hou H; Freeman WR; Hostetler KY; Cheng L
    Eur J Pharm Biopharm; 2015 Jan; 89():271-9. PubMed ID: 25513956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel oil-based suspension of a micro-environmental, pH-modifying solid dispersion for parenteral delivery: Formulation and stability evaluation.
    Zhang S; Wan Q; Xu X; Xing Y; Ding J; Yang S; Sun W; Lu M; Pan B
    Colloids Surf B Biointerfaces; 2019 Jul; 179():382-392. PubMed ID: 30999117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac.
    Durairaj C; Kim SJ; Edelhauser HF; Shah JC; Kompella UB
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4887-97. PubMed ID: 19516015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-formulation and chemical stability studies of penethamate, a benzylpenicillin ester prodrug, in aqueous vehicles.
    Jain R; Wu Z; Bork O; Tucker IG
    Drug Dev Ind Pharm; 2012 Jan; 38(1):55-63. PubMed ID: 21696334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration.
    Kim H; Csaky KG; Gravlin L; Yuan P; Lutz RJ; Bungay PM; Tansey G; DE Monasterio F; Potti GK; Grimes G; Robinson MR
    Retina; 2006; 26(5):523-30. PubMed ID: 16770258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes.
    Lode HE; Gjølberg TT; Foss S; Sivertsen MS; Brustugun J; Andersson Y; Jørstad ØK; Moe MC; Andersen JT
    Sci Rep; 2019 Dec; 9(1):18021. PubMed ID: 31792234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-Carnosine: multifunctional dipeptide buffer for sustained-duration topical ophthalmic formulations.
    Singh SR; Carreiro ST; Chu J; Prasanna G; Niesman MR; Collette Iii WW; Younis HS; Sartnurak S; Gukasyan HJ
    J Pharm Pharmacol; 2009 Jun; 61(6):733-42. PubMed ID: 19505363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of different preparation methods for a preservative free triamcinolone acetonide preparation for intravitreal administration: a validated stability indicating HPLC-method.
    Korodi T; Lachmann B; Kopelent-Frank H
    Pharmazie; 2010 Dec; 65(12):860-6. PubMed ID: 21284253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injectable formulations for an intravitreal sustained-release application of a novel single-chain VEGF antibody fragment.
    Asmus LR; Grimshaw JP; Richle P; Eicher B; Urech DM; Gurny R; Möller M
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):250-60. PubMed ID: 25779352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947.
    Liu X; Liang X; LeCouter J; Ubhayakar S; Chen J; Cheng J; Lee T; Lubach J; Nonomiya J; Shahidi-Latham S; Quiason C; Solon E; Wright M; Hop CECA; Heffron TP
    Drug Metab Dispos; 2020 May; 48(5):408-419. PubMed ID: 32132091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ULTRASONOGRAPHIC FINDINGS IN THE VITREOUS OF PATIENTS WITH AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.
    Mato-Gondelle T; Bande MF; Paniagua L; Rodríguez-Cid MJ; Abraldes M; Fernández M; Blanco-Teijeiro MJ; Piñeiro A
    Retina; 2018 Oct; 38(10):1962-1967. PubMed ID: 28820850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops.
    Loftsson T; Hreinsdóttir D; Stefánsson E
    J Pharm Pharmacol; 2007 May; 59(5):629-35. PubMed ID: 17524227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A minimally invasive jet injector for intravitreal and subconjunctival injection.
    Peyman GA; Hosseini K; Cormier M
    Ophthalmic Surg Lasers Imaging; 2012; 43(1):57-62. PubMed ID: 22251846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
    Sawada O; Miyake T; Kakinoki M; Sawada T; Kawamura H; Ohji M
    Retina; 2010; 30(7):1034-8. PubMed ID: 20616682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a topical suspension containing three active ingredients.
    Chang HC; Li LC; Toongsuwan S; Stephens D; Liu RM; Plichta-Mahmoud H
    Drug Dev Ind Pharm; 2002 Jan; 28(1):29-39. PubMed ID: 11858522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.